Form 8-K - Current report:
SEC Accession No. 0001213900-25-057139
Filing Date
2025-06-24
Accepted
2025-06-24 14:35:40
Documents
15
Period of Report
2025-06-24
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0246768-8k_inmed.htm   iXBRL 8-K 28127
2 NEWS RELEASE, DATED JUNE 24, 2025 ea024676801ex99-1_inmed.htm EX-99.1 21325
3 GRAPHIC ex99-1_001.jpg GRAPHIC 16114
  Complete submission text file 0001213900-25-057139.txt   269545

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inm-20250624.xsd EX-101.SCH 3020
5 XBRL DEFINITION FILE inm-20250624_def.xml EX-101.DEF 26194
6 XBRL LABEL FILE inm-20250624_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE inm-20250624_pre.xml EX-101.PRE 22363
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0246768-8k_inmed_htm.xml XML 3670
Mailing Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8
Business Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 251068246
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)